On November 1, 2021, Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) announced that the oncolytic virus product Delytact (teserpaturev/G47∆) has been approved to the Ministry of Health
On September 25, Sinopharms China Biotech mRNA vaccine industrialization base officially started in Jiading, Shanghai. On September 25, Sinopharms China Biotech mRNA vaccine indus
October 10, 2021/eMedClub News/--Recently, the 2021 Oncolytic Virus Drug Development Forum co-sponsored by eMedClub, InnoMicro and HeyuanBio was successfully held in Shanghai Ever
Effect picture CNBG-VIROGIN BIOTECH(SHANGHAI)CO.,LTD. purchased about 20 acres of land in Nanxiang Town, Jiading, Shanghai. The planned land area of the project is 13,431.500 squa
On May 14th, Zhu Jingjin, Secretary of the Party Committee and Vice President of China Biology, and Zhang Yuntao, Vice President and Chief Scientist, and his delegation visited Zh
On June 28, 2020, the clinical application of CNBG-VIROGINs first oncolytic virus drug was accepted by the NMPA. In 2015, the FDA approved the only oncolytic virus therapy so far-